Downregulation of calcitonin receptor mRNA expression by calcitonin during human osteoclast-like cell differentiation.
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Calcitonin inhibits both osteoclast formation and bone resorption, and is a primary treatment for patients with hypercalcemia and increased bone turnover. However, the clinical utility of calcitonin is limited because patients become refractory to calcitonin after several days (the calcitonin "escape phenomenon"). The molecular basis for calcitonin "escape" is unclear. To determine the regulatory mechanisms controlling calcitonin receptor (CTR) expression in osteoclasts and their precursors, we treated immature mononuclear precursors for human osteoclast-like multinucleated cells (MNC) formed in vitro with 1,25-(OH)2D3, to induce their differentiation to committed mononuclear precursors, and mature multinucleated osteoclasts, and used reverse transcriptase (RT)-PCR to assess expression of CTR mRNA in both committed mononuclear precursors and MNC. The PCR fragment produced was cloned and sequenced to confirm that it was derived from CTR mRNA. CTR mRNA expression was detected in mononuclear MNC precursors after 7 d of 1,25-(OH)2D3 treatment. It was also present in osteoclast-like MNC and highly purified giant cells from osteoclastomas, but not in monocytes or macrophage polykaryons formed in vitro. Calcitonin markedly decreased CTR but not actin mRNA expression in giant cells and MNC after 12 h, and removal of calcitonin restored CTR mRNA expression. Similarly, calcitonin decreased calcitonin-induced adenylate cyclase activity. These data suggest: (a) downregulation of CTR gene expression by calcitonin may in part explain the calcitonin "escape phenomenon"; and (b) expression of CTR mRNA occurs in mononuclear osteoclast precursors within 7 d after exposure to 1,25-(OH)2D3.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The desensitization of the cells to calcitonin was found to be the result of a ligand-induced internalization of the CTR, as well as inhibition of de novo synthesis of the receptor, and has been confirmed in both human and murine osteoclast cultures (194,212).”
From The Activity of Peptides of the Calcitonin Family in Bone (2019) · cites this paper as [194]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease
Chirgwin, J. M., Przybyla, A. E., MacDonald, R. J., & Rutter, W. J. (1979) · Biochemistry · doi:10.1021/bi00591a005 · Cited by 21,725
A highly sensitive adenylate cyclase assay
Salomon, Y., Londos, C., & Rodbell, M. (1974) · Analytical Biochemistry · doi:10.1016/0003-2697(74)90222-x · Cited by 4,169
Pfeilschifter, J., Chenu, C., Bird, A., Mundy, G. R., & Roodman, D. G. (1989) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650040116 · Cited by 468
Nicholson, G. C., Moseley, J. M., Sexton, P. M., Mendelsohn, F. A., & Martin, T. J. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112584 · Cited by 454
CHAMBERS, T. J., McSHEEHY, P. M. J., THOMSON, B. M., & FULLER, K. (1985) · Endocrinology · doi:10.1210/endo-116-1-234 · Cited by 422
Ng, S.-Y., Gunning, P., Eddy, R., Ponte, P., Leavitt, J., Shows, T., & Kedes, L. (1985) · Molecular and Cellular Biology · doi:10.1128/mcb.5.10.2720-2732.1985 · Cited by 372
Davies, J., Warwick, J., Totty, N., Philp, R., Helfrich, M., & Horton, M. (1989) · The Journal of cell biology · doi:10.1083/jcb.109.4.1817 · Cited by 365
KURIHARA, N., CHENU, C., MILLER, M., CIVIN, C., & ROODMAN, G. D. (1990) · Endocrinology · doi:10.1210/endo-126-5-2733 · Cited by 227
Self-citationGorn, A. H., Lin, H. Y., Yamin, M., Auron, P. E., Flannery, M. R., Tapp, D. R., Manning, C. A., Lodish, H. F., Krane, S. M., & Goldring, S. R. (1992) · Journal of Clinical Investigation · doi:10.1172/jci116046 · Cited by 211
Self-citationNg, S. Y., Gunning, P., Eddy, R., Ponte, P., Leavitt, J., Shows, T., & Kedes, L. (1985) · Molecular and Cellular Biology · doi:10.1128/mcb.5.10.2720 · Cited by 209
Research works printed but not linked: 2
- [3]3. Bouizar, Z., W. H. Rostene, and G. Milhaud. 1987. Downregulation of rat kidney calcitonin receptors by salmon calcitonin infusion evidenced by autoradiography. Proc. Natl. Acad. Sci. USA. 84:5125–5128. J.
- [43]43. Lin, M. C., J. Rajfer, R. S. Swerdloff, and N. F. Gonzalez-Cadavid. 1993. Testosterone down-regulates the levels of androgen receptor mRNA in smooth mu 'us at a ti csa avu aia a oa s eusn Steroid Biochem. Mol. Biol. 45(5):333–343.
Cited by
Chesnut, C. H., Silverman, S., Andriano, K., Genant, H., Gimona, A., Harris, S., Kiel, D., LeBoff, M., Maricic, M., Miller, P., et al. (2000) · The American Journal of Medicine · doi:10.1016/s0002-9343(00)00490-3 · Cited by 1,122
Becker, K. L., Nylén, E. S., White, J. C., Müller, B., & Snider, R. H. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021444 · Cited by 578
Cell biology of the osteoclast
Roodman, G. D. (1999) · Experimental Hematology · doi:10.1016/s0301-472x(99)00061-2 · Cited by 571
“Calcitonin downregulates expression of CTR in osteoclast precursors and mature osteoclasts in part by inhibiting CTR mRNA expression [88].”
BackgroundSelf-citationZara, J. N., Siu, R. K., Zhang, X., Shen, J., Ngo, R., Lee, M., Li, W., Chiang, M., Chung, J., Kwak, J., et al. (2011) · Tissue Engineering Part A · doi:10.1089/ten.tea.2010.0555 · Cited by 560
Gravallese, E. M., Harada, Y., Wang, J. T., Gorn, A. H., Thornhill, T. S., & Goldring, S. R. (1998) · Europe PMC (PubMed Central) · Cited by 516
Self-citationVI. Meta-Analysis of Calcitonin for the Treatment of Postmenopausal Osteoporosis
Cranney, A., Tugwell, P., Zytaruk, N., Robinson, V., Weaver, B., Shea, B., Wells, G., Adachi, J., Waldegger, L., Guyatt, G., et al. (2002) · Endocrine Reviews · doi:10.1210/er.2001-6002 · Cited by 286
“There is also concern that prolonged exposure to calcitonin may down-regulate the calcitonin receptors on osteoclasts, which could allow the osteoclasts to recover from the suppressive action of calcitonin (9).”
BackgroundMolecular and cellular biology of alveolar bone
SODEK, J., & MCKEE, M. D. (2000) · Periodontology 2000 · doi:10.1034/j.1600-0757.2000.2240106.x · Cited by 283
Gelsolin Deficiency Blocks Podosome Assembly and Produces Increased Bone Mass and Strength
Chellaiah, M., Kizer, N., Silva, M., Alvarez, U., Kwiatkowski, D., & Hruska, K. A. (2000) · The Journal of Cell Biology · doi:10.1083/jcb.148.4.665 · Cited by 257
“The migrating cells were visible as a black body (Takahashi et al., 1995).”
BackgroundHormonal Control of Calcium Homeostasis
Mundy, G. R., & Guise, T. A. (1999) · Clinical Chemistry · doi:10.1093/clinchem/45.8.1347 · Cited by 222
Salmon calcitonin: a review of current and future therapeutic indications
Chesnut, C. H., Azria, M., Silverman, S., Engelhardt, M., Olson, M., & Mindeholm, L. (2008) · Osteoporosis International · doi:10.1007/s00198-007-0490-1 · Cited by 216
“Physiologic down-regulation of calcitonin receptor sites has been reported [26] but is of uncertain clinical significance.”
BackgroundRamaswamy, Y., Wu, C., Van Hummel, A., Combes, V., Grau, G., & Zreiqat, H. (2008) · Biomaterials · doi:10.1016/j.biomaterials.2008.08.006 · Cited by 188
Gastric Acid, Calcium Absorption, and Their Impact on Bone Health
Kopic, S., & Geibel, J. P. (2013) · Physiological Reviews · doi:10.1152/physrev.00015.2012 · Cited by 176
“Today we know that the transient effect of calcitonin on osteoclasts is attributable to a downregulation of surface calcitonin receptors and their synthesis (882, 1061, 1129, 1130).”
BackgroundComparative Tolerability of Drug Therapies for Hypercalcaemia of Malignancy
Zojer, N., Keck, A. V., & Pecherstorfer, M. (1999) · Drug Safety · doi:10.2165/00002018-199921050-00004 · Cited by 167
Forty years of calcitonin—where are we now? A tribute to the work of Iain Macintyre, FRS
Zaidi, M., Inzerillo, A. M., Moonga, B. S., Bevis, P. J. R., & Huang, C. L.-H. (2002) · Bone · doi:10.1016/s8756-3282(02)00688-9 · Cited by 151
The Activity of Peptides of the Calcitonin Family in Bone
Naot, D., Musson, D. S., & Cornish, J. (2019) · Physiological Reviews · doi:10.1152/physrev.00066.2017 · Cited by 141
“The desensitization of the cells to calcitonin was found to be the result of a ligand-induced internalization of the CTR, as well as inhibition of de novo synthesis of the receptor, and has been confirmed in both human and murine osteoclast cultures (194, 212).”
Migration of human monocytes in response to procalcitonin
Wiedermann, F. J., Kaneider, N. C., Egger, P., Tiefenthaler, W., Wiedermann, C. J., Lindner, K. H., & Schobersberger, W. (2002) · Critical Care Medicine · doi:10.1097/00003246-200205000-00025 · Cited by 125
“(12) showed that the chemotactic response of monocytes obtained from patients who were chronically treated with either salmon CT or carbo-CT is impaired, thus suggesting a phenomenon of down-regulation of a common CT receptor known to be expressed on monocytes (32, 33).”
BackgroundDarling, J. M., Goldring, S. R., Harada, Y., Handel, M. L., Glowacki, J., & Gravallese, E. M. (1997) · Europe PMC (PubMed Central) · Cited by 125
Self-citationGenetic mouse models for bone studies—Strengths and limitations
Elefteriou, F., & Yang, X. (2011) · Bone · doi:10.1016/j.bone.2011.08.021 · Cited by 139
“TRAP is indeed highly expressed in differentiated osteoclasts [94] and this characteristic was used to generate the mouse Trap-Cre transgenic line.”
Lee, S. K. (1995) · Endocrinology · doi:10.1210/en.136.10.4572 · Cited by 118
Self-citationMolecular Pharmacology of the Calcitonin Receptor
Purdue, B. W., Tilakaratne, N., & Sexton, P. M. (2002) · Receptors and Channels · doi:10.1080/10606820213681 · Cited by 113
Transgenic mice that express Cre recombinase in osteoclasts
Chiu, W. S. M., McManus, J. F., Notini, A. J., Cassady, A. I., Zajac, J. D., & Davey, R. A. (2004) · genesis · doi:10.1002/gene.20041 · Cited by 100
Calcitonin Therapy in Osteoporosis
Muñoz‐Torres, M., Alonso, G., & Raya, P. M. (2004) · Treatments in Endocrinology · doi:10.2165/00024677-200403020-00006 · Cited by 111
Sondergaard, B. C., Wulf, H., Henriksen, K., Schaller, S., Oestergaard, S., Qvist, P., Tankó, L. B., Bagger, Y. Z., Christiansen, C., & Karsdal, M. A. (2006) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2006.01.014 · Cited by 88
Lundberg, P., Lie, A., Bjurholm, A., Lehenkari, P. P., Horton, M. A., Lerner, U. H., & Ransjö, M. (2000) · Bone · doi:10.1016/s8756-3282(00)00394-x · Cited by 88
Boonen, S., Body, J., Boutsen, Y., Devogelaer, J., Goemaere, S., Kaufman, J., Rozenberg, S., & Reginster, J. (2005) · Osteoporosis International · doi:10.1007/s00198-004-1812-1 · Cited by 96
“Down-regulation of calcitonin receptors on osteoclasts by long-term exposure has also been reported to decrease calcitonin activity [32].”
BackgroundWoo, J.-T., Kawatani, M., Kato, M., Shinki, T., Yonezawa, T., Kanoh, N., Nakagawa, H., Takami, M., Lee, K. H., Stern, P. H., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505663103 · Cited by 88
Calcitonin and Bone Physiology: In Vitro, In Vivo, and Clinical Investigations
Xie, J., Guo, J., Kanwal, Z., Wu, M., Lv, X., Ibrahim, N. A., Li, P., Buabeid, M. A., Arafa, E. A., & Sun, Q. (2020) · International Journal of Endocrinology · doi:10.1155/2020/3236828 · Cited by 83
Apone, S., Lee, M. Y., & Eyre, D. R. (1997) · Bone · doi:10.1016/s8756-3282(97)00105-1 · Cited by 72
Plosker, G. L., & McTavish, D. (1996) · Drugs & Aging · doi:10.2165/00002512-199608050-00006 · Cited by 78
Kim, J., Kim, E., Lee, B., Min, J.-H., Song, D.-U., LIM, J.-M., Eom, J.-W., Yeom, M., Jung, H., & Sohn, Y. (2016) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2016.2477 · Cited by 61
“The binding of calcitonin to its receptor has long been known to reduce osteoclast activation (4,31).”
Samura, A., Wada, S., Suda, S., Iitaka, M., & Katayama, S. (2000) · Endocrinology · doi:10.1210/endo.141.10.7715 · Cited by 54
Current Management Strategies for Hypercalcemia
Pecherstorfer, M., Brenner, K., & Zojer, N. (2003) · Treatments in Endocrinology · doi:10.2165/00024677-200302040-00005 · Cited by 54
Wada, S., Udagawa, N., Akatsu, T., Nagata, N., Martin, T. J., & Findlay, D. M. (1997) · Endocrinology · doi:10.1210/endo.138.2.4905 · Cited by 49
Faucheux, C., Nesbitt, S. A., Horton, M. A., & Price, J. S. (2001) · Journal of Experimental Biology · doi:10.1242/jeb.204.3.443 · Cited by 47
Wada, S. (1996) · Endocrinology · doi:10.1210/en.137.1.312 · Cited by 45
Sphene ceramics for orthopedic coating applications: An in vitro and in vivo study
Ramaswamy, Y., Wu, C., Dunstan, C. R., Hewson, B., Eindorf, T., Anderson, G. I., & Zreiqat, H. (2009) · Acta Biomaterialia · doi:10.1016/j.actbio.2009.04.028 · Cited by 45
Singer, F. R., & Krane, S. M. (1998) · Elsevier eBooks · doi:10.1016/b978-012068700-8/50020-7 · Cited by 44
Management of Osteoporosis in CKD Stages 3 to 5
Gordon, P., & Frassetto, L. A. (2010) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2010.02.338 · Cited by 47
Silverman, S. L. (2003) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(02)00060-9 · Cited by 43
Cytokine Regulation of Bone Cell Differentiation
Melissa, A. T., Guise, T. A., & Roodman, D. (1996) · Vitamins and hormones · doi:10.1016/s0083-6729(08)60407-0 · Cited by 46
Calcitonin: The Other Thyroid Hormone
Inzerillo, A. M., Zaidi, M., & Huang, C. L.-H. (2002) · Thyroid · doi:10.1089/105072502760339352 · Cited by 55
Serial cellular events in bone formation initiated by calcium phosphate ceramics
Guo, X., Li, M., Qi, W., Bai, H., Nie, Z., Hu, Z., Xiao, Y. M., de Bruijn, J. D., Bao, C., & Yuan, H. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.07.037 · Cited by 41
Nakagawa, H., Takami, M., Udagawa, N., Sawae, Y., Suda, K., Sasaki, T., Takahashi, N., Wachi, M., Nagai, K., & Woo, J. T. (2003) · Bone · doi:10.1016/s8756-3282(03)00201-1 · Cited by 39
Biskobing, D. M., & Fan, D. (2000) · Calcified Tissue International · doi:10.1007/s00223001107 · Cited by 38
“Increased CTR mRNA expression has been described in response to glucocorticoid treatment [17], whereas decreased expression has been demonstrated with calcitonin treatment [3, 16, 17, 18].”
BackgroundRakopoulos, M., Ikegame, M., Findlay, D. M., Martin, T. J., & Moseley, J. M. (1995) · Bone · doi:10.1016/8756-3282(95)00280-8 · Cited by 38
Ikegame, M., Rakopoulos, M., Martin, T. J., Moseley, J. M., & Dr. Findlay, D. M. (1996) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650110406 · Cited by 36
Inoue, D., Shih, C., Galson, D. L., Goldring, S. R., Horne, W. C., & Baron, R. (1999) · Endocrinology · doi:10.1210/endo.140.3.6551 · Cited by 40
Self-citationCalcitonin: Physiological Actions and Clinical Applications
Inzerillo, A. M., Zaidi, M., & Huang, C. L.-H. (2004) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem.2004.17.7.931 · Cited by 36
In Vitro Generation of Mature Human Osteoclasts
Hemingway, F., Cheng, X., Knowles, H. J., Martínez, F. O., Gordon, S., & Athanasou, N. A. (2011) · Calcified Tissue International · doi:10.1007/s00223-011-9530-0 · Cited by 34
“Osteoclasts continuously exposed to calcitonin can escape this inhibitory effect [20]; this was seen to some extent in our cultures where inhibition of resorption relative to the plain medium control was found to be not as marked at 96 hours compared to 24 hours.”
BackgroundResultOsteoporotic Vertebral Compression Fractures: Surgery versus Non-Operative Management
Tang, H., Zhao, J., & Hao, C. (2011) · Journal of International Medical Research · doi:10.1177/147323001103900432 · Cited by 31
Li, M., Li, H., Li, L., Liu, L., Chen, G., Jiang, W., Xu, W., Zhu, C., Yao, G., & Fang, S. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01023 · Cited by 30
Pham, V., Dong, M., Wade, J. D., Miller, L. J., Morton, C. J., Ng, H., Parker, M. W., & Sexton, P. M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m503272200 · Cited by 29
Monier‐Faugere, M., Geng, Z., Qi, Q., Arnala, I., & Malluche, H. H. (1996) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650110405 · Cited by 33
Ikegame, M., Ejiri, S., & Ozawa, H. (2004) · Bone · doi:10.1016/j.bone.2004.03.018 · Cited by 31
Woo, J., Yonezawa, T., Cha, B., Teruya, T., & Nagai, K. (2008) · Journal of Pharmacological Sciences · doi:10.1254/jphs.fm0070288 · Cited by 27
Kaskani, E., Lyritis, G. P., Kosmidis, C., Galanos, A., Andypas, G., Chorianopoulos, K., Giagiosis, A., Iliadou, K., Karagianis, A., Katsimichas, K., et al. (2005) · Clinical Rheumatology · doi:10.1007/s10067-004-1004-6 · Cited by 27
Wada, S., Yasuda, S., Nagai, T., Maeda, T., Kitahama, S., Suda, S., Findlay, D. M., Iitaka, M., & Katayama, S. (2001) · Endocrinology · doi:10.1210/endo.142.4.8085 · Cited by 24
Pei, J., Bingyun, L., Yanhui, G., Xu, J., Darko, G. M., & Sun, D. (2016) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2016.08.001 · Cited by 24
Xie, R., Kuijpers‐Jagtman, A. M., & Maltha, J. C. (2008) · Acta Odontologica Scandinavica · doi:10.1080/00016350802317488 · Cited by 20
Porous 3D Scaffolds Enhance MSC Vitality and Reduce Osteoclast Activity
Spreda, M., Hauptmann, N., Lehner, V., Biehl, C., Liefeith, K., & Lips, K. S. (2021) · Molecules · doi:10.3390/molecules26206258 · Cited by 19
Kudo, O., Sabokbar, A., Pocock, A., Itonaga, I., & Athanasou, N. A. (2002) · Calcified Tissue International · doi:10.1007/s00223-001-2128-1 · Cited by 21
“The mechanism responsible for this escape phenomenon is unclear but it may be due to an effect of calcitonin on transcriptional regulation of CTR gene expression and downregulation of CTR on the osteoclast surface [22].”
BackgroundWada, S. (1997) · Endocrinology · doi:10.1210/en.138.2.521 · Cited by 17
Ross, F. P., & Teitelbaum, S. L. (2001) · Elsevier eBooks · doi:10.1016/b978-012470862-4/50004-0 · Cited by 19
Phosphorylation of the Human Calcitonin Receptor by Multiple Kinases Is Localized to the C-Terminus
Nygaard, S. C., Kuestner, R. E., Moore, E. E., & Stroop, S. D. (1997) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1997.12.10.1681 · Cited by 16
Identification of a novel calcitonin-response element in the promoter of the human p21WAF1/CIP1 gene
Evdokiou, A., Raggatt, L. J., Sakai, T., & Findlay, D. (2000) · Journal of Molecular Endocrinology · doi:10.1677/jme.0.0250195 · Cited by 18
“The action most intensively studied to date is the CT-induced receptor down-regulation in mouse (Rakopoulos et al. 1995, Wada et al. 1995, 1996, Ikegame et al. 1996) and human (Takahashi et al. 1995, Inou et al. 1999) osteoclasts.”
BackgroundYasuda, S., Wada, S., Arao, Y., Kogawa, M., Kayama, F., & Katayama, S. (2004) · Endocrinology · doi:10.1210/en.2003-0862 · Cited by 17
“• Interaction between CTR 3 UTR and ARE-Binding Proteins Endocrinology, April 2004, 145(4):1730–1738 1731”
BackgroundResultInfluentialMolecular and Clinical Pharmacology of Calcitonin
Zaidi, M., Inzerillo, A. M., Troen, B. R., Moonga, B. S., Abe, E., & Burckhardt, P. (2002) · Elsevier eBooks · doi:10.1016/b978-012098652-1.50184-0 · Cited by 16
Ghoroghi, F. M., Moshkdanian, G., Sehat, M., Nematollahi‐Mahani, S. N., Kashani, I. R., & Pasbakhsh, P. (2018) · PubMed Central · doi:10.22074/cellj.2018.4737 · Cited by 14
“However, the current study results contrasted studies which have reported downregulation of the calcitonin receptor in osteoclasts after calcitonin administration (53).”
ResultBeaudreuil, J., Taboulet, J., Orcel, P., Graulet, A. M., Denne, M. A., Baudoin, C., Jullienne, A., & de Vernejoul, M. C. (2000) · Bone · doi:10.1016/s8756-3282(00)00305-7 · Cited by 16
Fan, X., Biskobing, D. M., Bain, S. D., & Rubin, J. D. (1996) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650110912 · Cited by 14
Gaasch, J. A., Bolwahnn, A. B., & Lindsey, J. S. (2006) · Gene · doi:10.1016/j.gene.2005.10.036 · Cited by 13
“activity, is of limited use because patients become resistant to it after several days due to hormone-induced receptor loss (Rakopoulos et al., 1995; Rodan and Martin, 2000; Takahashi et al., 1995).”
BackgroundOngphiphadhanakul, B., Piaseu, N., Chailurkit, L., & Rajatanavin, R. (1998) · Calcified Tissue International · doi:10.1007/s002239900448 · Cited by 13
“down regulation of calcitonin receptor [23], development of”
BackgroundGalvin, R. J. S., Bryan, P. M., Venugopalan, M., Smith, D. P., & Thomas, J. E. (1998) · Bone · doi:10.1016/s8756-3282(98)00096-9 · Cited by 15
Kukita, T., Kukita, A., Watanabe, T., & Iijima, T. (2001) · Journal of Endocrinology · doi:10.1677/joe.0.1700175 · Cited by 9
“It has also been demonstrated that the synthesis of CTR is suppressed at the transcription level when osteoclast-like multinucleated cells (MNCs) are treated with calcitonin ( Takahashi et al. 1995, Findlay & Martin 1997).”
BackgroundHigh Concentrations of Polyelectrolyte Complex Nanoparticles Decrease Activity of Osteoclasts
Kauschke, V., Hessland, F. M., Vehlow, D., Müller, M., Heiß, C., & Lips, K. S. (2019) · Molecules · doi:10.3390/molecules24122346 · Cited by 9
“This is accomplished by calcitonin inducing loss of the ruffled border [43,44], preventing osteoclast formation [45] and subsequently declining osteoclast numbers [42].”
BackgroundSilverman, S. L. (2001) · Rheumatic Disease Clinics of North America · doi:10.1016/s0889-857x(05)70193-9 · Cited by 9
Findlay, D. M., Houssami, S., Christopoulos, G., & Sexton, P. M. (1996) · Endocrinology · doi:10.1210/endo.137.11.8895320 · Cited by 9
Oura, S., Tanino, H., Yoshimasu, T., Sakurai, T., Nakamura, T., Kokawa, Y., Matsuyama, K., Ohta, F., & Naito, Y. (2000) · Breast Cancer · doi:10.1007/bf02966395 · Cited by 8
Tekeoğlu, İ., Adak, B., Budancamanak, M., Demirel, A., & Ediz, L. (2005) · Rheumatology International · doi:10.1007/s00296-004-0549-7 · Cited by 8
Salo, J. (2002) · Cited by 11
The Structure and Molecular Biology of the Calcitonin Receptor
Goldring, S. R. (1998) · Advances in organ biology · doi:10.1016/s1569-2590(08)60113-5 · Cited by 8
Self-citationHiraga, T., Takada, M., Nakajima, T., & Ozawa, H. (1996) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/s0278-2391(96)90492-9 · Cited by 7
Calcitonin for the treatment of osteoporosis: dosage and dosing interval in Japan.
Yamauchi, H., Suzuki, H., & Orimo, H. (2003) · PubMed · doi:10.1007/s00774-003-0409-7 · Cited by 8
“Clinically, downregulation has been associated with the use of CT for the treatment of hypercalcemia [55,56].”
BackgroundDisorders of Calcium Metabolism
Heras-Herzig, A., & Guise, T. A. (2008) · Elsevier eBooks · doi:10.1016/b978-012088488-9.50070-x · Cited by 7
Roach, J., Choi, S. J., Schaub, R. L., Leach, R. J., Roodman, G. D., & Reddy, S. V. (1998) · Gene · doi:10.1016/s0378-1119(97)00609-4 · Cited by 6
Self-citationMartin, T. J., Findlay, D. M., Moseley, J. M., & Sexton, P. M. (1998) · Elsevier eBooks · doi:10.1016/b978-012068700-8/50005-0 · Cited by 7
Structure and Molecular Biology of the Calcitonin Receptor
Galson, D. L., & Goldring, S. R. (2002) · Elsevier eBooks · doi:10.1016/b978-012098652-1.50136-0 · Cited by 9
Self-citationEfficacy and Tolerability of Calcitonin in the Prevention and Treatment of Osteoporosis
Reginster, Y., & Reginster, J. (1998) · BioDrugs · doi:10.2165/00063030-199810040-00004 · Cited by 9
Systemic and Local Regulators of Bone Remodeling
Hurley, M. M., & Lorenzo, J. (2004) · Springer eBooks · doi:10.1007/978-1-4471-3777-1_3 · Cited by 6
Biology, Physiology, and Morphology of Bone
Rubin, J. E., & Rubin, C. T. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-3285-4.10004-x · Cited by 5
Influência da calcitonina na reparação óssea de tíbias de ratas ovariectomizadas
Arisawa, E. Â. L. S., da Rocha, R. F., Carvalho, Y. R., Moraes, E., & Almeida, J. D. (2010) · Brazilian Dental Science · doi:10.14295/bds.2000.v3i1.71 · Cited by 4
Kirk, J. K., & Hepfinger, C. A. (2005) · Clinical Reviews in Bone and Mineral Metabolism · doi:10.1385/bmm:3:1:039 · Cited by 4
Kukita, T., Hiura, H., Gu, J.-Y., Zhang, J.-Q., Kyumoto‐Nakamura, Y., Uehara, N., Murata, S., Sonoda, S., Yamaza, T., Takahashi, I., et al. (2021) · Laboratory Investigation · doi:10.1038/s41374-021-00633-2 · Cited by 3
“The mechanism of this clinically identified phenomenon, the so-called “escape phenomenon,” is thought to be attributed to the suppression of the expression of CTRs at the transcriptional level [38]; however, an alternative mechanism is supposed to be involved in the regulatory process of osteoclast formation.”
BackgroundNaot, D., Musson, D. S., & Cornish, J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814841-9.00033-6 · Cited by 4
Molecular biology and regulation of the calcitonin receptor
Goldring, S. R. (1997) · Journal of Bone and Mineral Metabolism · doi:10.1007/bf02490074 · Cited by 2
“Based on observations in marrow culture systems in which osteoclastlike cells have been induced, the expression of the CT receptor appears to occur late in the sequence of osteoclast differentiation associated with the process of multinucleation and acquisition of the capacity to resorb bone [46,68-71].”
BackgroundSelf-citationAmylin and Calcitonin Gene-Related Peptide
Naot, D., Reid, I. R., & Cornish, J. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-373884-4.00056-2 · Cited by 2
Silverman, S. L. (2003) · Clinics in Geriatric Medicine · doi:10.1016/s0749-0690(02)00070-8 · Cited by 2
Calcitonin Treatment in Postmenopausal Osteoporosis
Silverman, S. L. (2000) · Elsevier eBooks · doi:10.1016/b978-012068705-3/50010-3 · Cited by 2
Basic Aspects of Calcitonin in Skeletal Health
Gennari, C. (2003) · Humana Press eBooks · doi:10.1007/978-1-59259-278-4_20 · Cited by 1
DISORDERS OF CALCIUM METABOLISM AND BONE MINERALIZATION
Clarke, B. L., & Khosla, S. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-3291-5.50043-3 · Cited by 1
Metadata
- Authors
- Takahashi, S., Goldring, S., Katz, M., Hilsenbeck, S., Williams, R., & Roodman, G. D.
- Affiliations
- United States Department of Veterans Affairs (US)
- Harvard University (US)
- The University of Texas at San Antonio Health Science Center (US)
- Venue
- Journal of Clinical Investigation
- Published
- 1995-01-01
- Volume
- 95
- Issue
- 1
- Pages
- 167-171
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC295397
- OpenAlex
- W1975884885
- Cited by
- 125
- References
- 44
- Citations by year
- 2026: 2 · 2025: 1 · 2023: 2 · 2021: 3 · 2020: 2 · 2019: 3 · 2018: 2 · 2016: 2 · 2014: 1 · 2013: 1 · 2012: 1
- FWCI
- 3.35
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (1r01am035188-01)
- National Cancer Institute (P30CA 54174)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (AR 39539, AR41336, R01AR041336)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Nephrology › Parathyroid Disorders and Treatments
- Keywords
- calcitonin receptor, calcitonin, osteoclastogenesis, osteoclast-like multinucleated cells, osteoclast precursors, receptor down-regulation, 1,25-dihydroxyvitamin D3, adenylate cyclase, bone resorption, hypercalcemia
- MeSH terms
- Base Sequence, Bone Marrow, Bone Marrow Cells, Calcitonin, Calcitriol, Cell Differentiation, Cells, Cultured, Humans, Macrophages, Molecular Sequence Data, Monocytes, Osteoclasts, RNA, Messenger, Stem Cells, Down-Regulation, Polymerase Chain Reaction, Receptors, Calcitonin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.